Giovanni Marconi

Giovanni Marconi

Ricercatore a tempo determinato senior (Tipo B) dell'Università di Bologna con convenzione assistenziale presso Unitá di Onco-ematologia,Ospedale S. Maria delle Croci, Ravenna (RA).

Nato a Ascoli Piceno il 23/03/1989

Indirizzo di lavoro: Ospedale Santa Maria delle Croci, Ravenna (RA)

Licenza medica numero 17312, albo professionale FnomCEO di Bologna

ORCID: orcid.org/0000-0001-6309-0515

SCOPUS ID: 56927880100

WOS ID: AAX-7449-2020

Sono un ematologo dedicato e affermato con un particolare interesse nella cura dellla leucemia mieloide acuta (AML) e della leucemia linfoblastica acuta (ALL). Il mio percorso in questo campo è iniziato nel 2012 quando ho intrapreso la mia formazione presso l'Istituto Serágnoli, U.O Ematologia, Ospedale S. Orsola di Bologna, dove ho sviluppato una profonda conoscenza dell'ematologia e affinato le mie capacità cliniche. A novembre 2020 ho conseguito il diploma di scuola di specializzazione in Ematologia. Nel corso della mia carriera, sono stato attivamente impegnato nella ricerca clinica, conducendo studi a livello istituzionale, locale e nazionale. I miei sforzi di ricerca si sono concentrati su AML e ALL dalla ricerca traslazionale a quella clinica, e ho contribuito a numerose pubblicazioni, inclusi articoli sottoposti a revisione paritaria e presentazioni a convegni internazionali. In particolare, sono stato coinvolto nella creazione e nella conduzione di studi clinici prospettici, che dovrebbero produrre risultati significativi nei prossimi anni. Guardando avanti, il mio obiettivo è continuare il mio percorso verso l'eccellenza nel campo delle leucemie acute. La mia passione per la ricerca e la dedizione al miglioramento dei risultati dei pazienti mi spingono a perseguire nuove frontiere ed esplorare approcci innovativi nel campo.

05 Febbraio 2021: EHA CLASSICAL MASTER CLASS 2019 – 2020, EHA ISCED 7-72

09 Novembre 2020: Diploma di scuola di specializzazione in Ematologia, Universitá di Bologna ISCED 8-72.

20 Febbraio 2015: Iscrizione all’ordine dei medici e chirurghi di Bologna, License Nr. 17312, FNOMCEO, Bologna.

21 Ottobre 2014: Laurea in Medicina e chirurgia, con una tesi di ricerca sulle Core Binding Factor Acute Myeloid Leukemia, ISCED 6-72.

Luglio 2009: “maturità classica”, votazione finale 100/100, ISCED 3-22.

Dal 15 Novembre 2020 al 14 Febbraio 2024: Dirigente medico di I livello presso l’Unitá di Onco-ematologia, Istituto di ricovero e cura a carattere scientifico (IRCCS) Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) “Dino Amadori”, Meldola (FC)

Dal 25 Marzo 2020 al 23 Novembre 2020: ‘CO.CO.CO’ presso l’unitá Covid-19 “intermediate care”AUSL di Bologna.

Dal 1 Novembre 2016 al 9 Novembre 2020: Scuola di specializzazione in Ematologia presso l’Istituto Serágnoli, U.O Ematologia, Ospedale S. Orsola di Bologna con il Prof. Michele Cavo come tutor.

Dal 1 Febbraio 2015 al 31 Gennaio 2016: tirocinio presso l’Istituto Serágnoli, U.O Ematologia, Ospedale S. Orsola con un progetto di ricerca dal titolo “Use of Next Generation Sequencing to Find Genetic Mutations in Patients with Core Binding Factor Acute Myeloid Leukemia and their Evaluation as Putative Independent Prognostic Markers”, con il Professor Giovanni Martinelli come tutor.

Da Settembre 2012 a Gennaio 2015: training presso Istituto Serágnoli, U.O Ematologia, Ospedale S. Orsola.

Lingua : italiano.

Altre lingue: English speaking good level (C1), writing good level (C1).

Informatica: Livello intermedio (Office, Access, OS Windows and Unix, SPSS, REDCap). Conoscenza della statistica medica.

7 Febbraio 2023 Basic Life Support and Defibrillator (BLS-D). 18 Marzo 22 Advanced Life Support (ALS). 8 Settembre 2022 Good Clinical Practice (GCP).

Ho lavorato nella progettazione di molti studi clinici spontanei e sponsorizzati dall'azienda. In particolare, ho lavorato come co-principal investigator in NCT03898128, NCT03455504, NCT03610438, NCT04070807, e sono stato incluso nello steering cometee dello studio MINIMAL (apertura), RIVER 81 (Ryvu, in apertura), RIVER 52 (Ryvu, in apertura), Astrazeneca (anti-CD123, in apertura).

Lavoro come principal investigator locale o sub-investigator in trial di fase I – II – III: Roche, Astellas, Cellgene, J&J, Novartis, Abbvie, Pfizer e studi spontanei. Coordinatore per l'Italia di NCT04797780.

Lavoro come coordinatore del registro BPDCN per ERN-EuroBloodNet.

Sono il coordinatore scientifico del progetto IMPACT-AML, finanziato nell'ambito di Horizon Europe Mission Cancer HORIZON-MISS-2022-CANCER-01 (responsabile del progetto: Giovanni Martinelli).

Partecipo come esperto a EUAfricaPerMED.

Partecipo al network leucemie acute all’interno del Comprehensive Cancer Care and Research Network della Romagna.

Docente per EHA Masterclass 2021-2022 e 2022-2023.

Docente nel Master di secondo livello in oncoematologia pediatrica, Universitá di Bologna, 2022.

Docente nel Master di secondo livello in farmacia oncologica, Universitá di Bologna, 2022.

Relatore ad oltre 50 congressi nazionali e internazionali.

1. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients; Alfonso Piciocchi et al; European Journal of Hematologym 2024, https://doi.org/10.1002/jha2.873
2. ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. Bochicchio MT, et al; International Journal of Molecular Sciences. 2024; 25(1):118. https://doi.org/10.3390/ijms25010118
3. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. Kayser S, et al; Haematologica. 2023 Dec 7. doi: 10.3324/haematol.2023.284310. PMID: 38058184.
4. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients. Ghetti M, et al. Biomed Pharmacother. 2023 Aug 1;165:115235. doi: 10.1016/j.biopha.2023.115235. PMID: 37536029.
5. Editorial: Precision medicine for acute myeloid leukemia. Marconi G, et al. Front Oncol. 2023 Jul 25;13:1233757. doi: 10.3389/fonc.2023.1233757. PMID: 37560469; PMCID: PMC10408292.
6. Personalizing precision medicine: Patients with AML perceptions about treatment decisions. Grauman Å, et al.; Patient Educ Couns. 2023 Jul 5;115:107883. doi: 10.1016/j.pec.2023.107883. Epub ahead of print. PMID: 37421687.
7. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. M. Mallo et al. EJHaem. 2023 Feb 7;4(2):446-449. doi: 10.1002/jha2.651.
8. AVALON Cooperative Group. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Todisco E., et al. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608.
9. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. Marconi et al., Cancer Med. 2023 Mar 31. doi: 10.1002/cam4.5858.
10. Hemophagocytic lymphohistiocytosis in gastric cancer: A rare syndrome for the oncologist. Case report and brief review. Monti M. et al., Front Oncol. 2023 Feb 8;13:1010561. doi: 10.3389/fonc.2023.1010561.
11. Biological therapy in elderly patients with acute myeloid leukemia. Ciotti et al, Expert Opin Biol Ther. 2023 Feb;23(2):175-194. doi: 10.1080/14712598.2023.2174015.
12. Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. Messina M, et al. Cancers (Basel). 2022 Jun 18;14(12):3012. doi: 10.3390/cancers14123012.
13. Post COVID-19 irritable bowel syndrome. Marasco G. et al, Gut. 2022 Dec 9:gutjnl-2022-328483. doi: 10.1136/gutjnl-2022-328483.
14. Baseline CD22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. Sartor C, et al. Hematol Oncol. 2022 May 26. doi: 10.1002/hon.3029.
15. Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents; Cristina Papayannidis, Jacopo Nanni et al.; Eur J Haematol. 2022 Feb 14. doi: 10.1111/ejh.13753.
16. Long-Term Outcome After Adoptive Immunotherapy with Natural Killer Cells: Alloreactive NK Cell Dose Still Matters; Parisi et al. Frontiers in Immunology; 12 2022; 10.3389/fimmu.2021.804988
17. Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Ciotti G, Marconi G, Martinelli G. Front Oncol. 2022 Jan 6;11:810387. doi: 10.3389/fonc.2021.810387. eCollection 2021.
18. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. Padella A, et al, J Hematol Oncol. 2022 Jan 22;15(1):10. doi: 10.1186/s13045-022-01228-0.
19. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Ravaioli F, Marconi G, et al., Cancer Med. 2022 Feb;11(3):618-629. doi: 10.1002/cam4.4390. Epub 2021 Dec 30.
20. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Wei, et al. Nat Commun 12, 6233 (2021). https://doi.org/10.1038/s41467-021-26551-x
21. Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. Marasco G et al. Am J Gastroenterol. 2021 Nov 9. doi: 10.14309/ajg.0000000000001541.
22. INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. Martinelli G et al; Blood Adv. 2021 Oct 14:bloodadvances.2021004821. doi: 10.1182/bloodadvances.2021004821.
23. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. Ragaini S, et al. Blood Adv. 2021 Sep 17. doi: 10.1182/bloodadvances.2021004878.
24. Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Cerchione C et al. Expert Rev Hematol. 2021 Sep;14(9):851-865. doi: 10.1080/17474086.2021.1969911. Epub 2021 Aug 30.
25. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. Simonetti G, et al. Leukemia. 2021 Oct;35(10):2813-2826. doi: 10.1038/s41375-021-01318-x. Epub 2021 Jun 30.
26. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Marconi G. et al., Expert Opin Drug Saf. 2021 Jul;20(7):791-799. doi: 10.1080/14740338.2021.1913120.
27. Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement. Cristiano G et al. Acta Haematol. 2021 Jun 15:1-5. doi: 10.1159/000516003. Online ahead of print.
28. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. Papayannidis C, et al. Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7.
29. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. Fontana MC, et al. Biomedicines. 2021 Apr 6;9(4):388. doi: 10.3390/biomedicines9040388.
30. Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. Padella A et al. Blood Cancer J. 2021 Jan 7;11(1):7. doi: 10.1038/s41408-020-00396-x.
31. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. Marconi G, et al. Leuk Res. 2021 Feb;101:106497. doi: 10.1016/j.leukres.2020.106497. Epub 2020 Dec 25.
32. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. Marconi G et al. Eur J Haematol. 2020 Jul;105(1):47-55. doi: 10.1111/ejh.13406. Epub 2020 Apr 7.
33. Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. Bruno S, et al. J Oncol. 2019 Oct 30;2019:5985923. doi: 10.1155/2019/5985923. eCollection 2019.
34. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. Ghelli Luserna Di Rorà A, et al. Cancers (Basel). 2019 Oct 25;11(11):1654. doi: 10.3390/cancers11111654.
35. Acute Myeloid Leukemia Mutations: Therapeutic Implications. Papayannidis C, et al. Int J Mol Sci. 2019 Jun 3;20(11):2721. doi: 10.3390/ijms20112721.
36. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Simonetti G, et al. Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.
37. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. Bertamini L, et al. BMC Cancer. 2018 Nov 15;18(1):1117. doi: 10.1186/s12885-018-5026-x.
38. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Corradi G, et al. Stem Cell Res Ther. 2018 Oct 25;9(1):271. doi: 10.1186/s13287-018-1013-z.
39. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Ghelli Luserna Di Rorà A, et al. J Hematol Oncol. 2018 Aug 1;11(1):99. doi: 10.1186/s13045-018-0641-1.
40. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Fontana MC, Marconi G et al. Leukemia. 2018 Jul;32(7):1609-1620. doi: 10.1038/s41375-018-0035-y. Epub 2018 Feb 23.
41. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. Tenti E, et al. Expert Opin Pharmacother. 2016 Dec;17(18):2479-2486. doi: 10.1080/14656566.2016.1258056. Epub 2016 Nov 21.
42. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Zuffa E, et al. Oncotarget. 2015 Oct 13;6(31):31284-94. doi: 10.18632/oncotarget.5161.

Principali comunicazioni a congress internazionali:

1. Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia. Giovanni Marconi et al.; Blood 2023; 142 (Supplement 1): 1536.
2. Safety and tolerability of AZD0466 as monotherapy for patients with advanced hematological malignancies - preliminary results from an ongoing phase I/II trial; EHA 2023; Giovanni Marconi et al.
3. Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation; ASH2022; Giovanni Marconi et al Blood (2022) 140 (Supplement 1): 6119–6121.
4. Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia; ASH 2022; Giovanni Marconi et al. Blood (2022) 140 (Supplement 1): 1705–1707.
5. Safety run-in cohort 1 of GIMEMA AML1718: a safety run-in and phase 2 open-label study of venetoclax, fludarabine, cyratabine and idarubicine (v-FLAI) in induction therapy of acute myeloid leukemia; EHA 2020; Giovanni Marconi et al.
6. Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozagomicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia; Blood; Volume 134, Issue Supplement_1, November 13 2019; Giovanni Marconi, Federico Ravaioli et al.
7. The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of Acute Myelogenous Leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; Giovanni Marconi et al.
8. Chromothripsis in AML patients: A new mechanism of cancer initiation and progression; cancer Research 76(14 Supplement): 3582-3582; Jul 2016; Maria Chiara Fontana, Giovanni Marconi et al;
9. Two or More Chemotherapy Consolidation Courses, Followed by Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients; Blood 2015 126:3198; Dec 2015; Giovanni Marconi et al.
   

Riconoscimenti e Finanziamenti 

2016

ASH Abstract Achievement Award: Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

2017

AACR-Pezcoller Foundation Award: 1. Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients

2017

Pfizer grants drug and financing ALL MRD positive (phase 2 clinical trial)

Ruolo: Scrittura dello studio; co-PI

2018

Abbvie grants drug and financing Venetoclax in combination with FLAI in AML (phase 1/2 clinical trial)

Ruolo: Scrittura dello studio; co-PI

2019

Pfizer grants data collection on inotuzumanb in ALL (phase 4 clinical trial)

Ruolo: Scrittura dello studio; co-PI

2019

AstraZeneca grants ex-vivo testing of AURK1 inhibitor nelle AML.

Ruolo: Scrittura dello studio

2019

ASH Abstract Achievement Award: Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

2020

EHA Abstract Achievement Award: Safety run-in cohort 1 of Gimema AML1718: a safety run-in and phase 2 open-label study of venetoclax, fludarabine, cyratabine and idarubicine (v-FLAI) in induction therapy of acute myeloid leukemia

2022

ASH/SIE Abstract Achievement Award: Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

2022

ASH/SIE Abstract Achievement Award: Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

2023

IMPACT-AML, Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia (P.I. Giovanni Martinelli) -Horizon Europe Mission Cancern. 101104421

Ruolo: Coordinator Contact, Scientific Project cohordinator

2024

RESOLVE, MRD registry and multicentre, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL (P.I. Michael Heuser) Horizon Europe Mission Cancer n. 101136502

Ruolo: partner

2024

MY FIRST AIRC (P.I. Giorgia Simonetti): Exploring polyamine metabolism as selective vulnerability for therapeutic combinations in acute myeloid leukemia

Ruolo: partner